Silence Therapeutics Stock Discussion

Despite strong growth, Silence Therapeutics' high P/S ratio and weak revenue outlook suggest a risk of share price decline. Analysts lack confidence in a business turnaround, indicating potential risk for shareholders and potential investors.

Analysts' confidence appears low for Silence Therapeutics' business turnaround. The high P/S ratio and expected revenue decline suggest unsustainable current price levels which may erode current sentiment towards the stock.